Home Industry Healthcare G42 Healthcare, ProPhase to collaborate on genomic sequencing capabilities, data insights In line with their collaboration, G42 Healthcare and ProPhase will also explore the creation of a genomic sequencing facility in the US by Gulf Business October 21, 2022 G42 Healthcare has signed a strategic memorandum of understanding (MoU) with ProPhase Precision Medicine, a wholly-owned subsidiary of ProPhase Labs, a diversified US-based diagnostics, genomics, and biotech company. G42 Healthcare and ProPhase will explore collaborative opportunities across different geographic markets focusing on, but not limited to, genomic sequencing, artificial intelligence, sharing genomic data insights, and obtaining advanced certifications. Ashish Koshy, CEO of G42 Healthcare, said: “We are thrilled with our strategic collaboration with ProPhase, which will help us expand the scale and scope – starting from genomic sequencing to advanced AI technologies and delivering valuable data insights for R&D and improved outcomes as part of our clinical genomics solutions.” He added: “We are confident that this partnership with ProPhase will deliver comprehensive genome data, biological insights, and healthcare outcomes for better personalised and preventive healthcare delivery.” “G42 Healthcare is an enabler of the world’s largest and one of the most comprehensive population genomics initiatives – the Emirati Genome Program, which aims to move the traditional ecosystem from sick care to preventive healthcare for UAE’s future citizens. G42 Healthcare is, therefore, an ideal potential partner for ProPhase as we look to bolster our next-generation sequencing capabilities and build our new state-of-the-art genomic sequencing facility,” said Ted Karkus, ProPhase Lab’s CEO. “We expect to realise cost savings through these objectives which we will pass on to our customers to accelerate sales growth. Together, ProPhase and G42 Healthcare are positioned at the forefront of genetic research which is set to play a key role in personalised precision medicine – the future of healthcare,” he added. In other developments, G42 Healthcare and Mubadala Health have recently partnered to create an integrated healthcare company. The new entity will leverage the strength of this combined network, which includes state-of-the-art healthcare facilities and digital platforms. Read: Mubadala Health, G42 Healthcare partner to create integrated entity Tags G42 Healthcare genomic sequencing Healthcare ProPhase Precision Medicine 0 Comments You might also like Informa’s Adam Andersen on how CPHI ME is building bridges in the pharma sector Mubadala-led consortium buys stake in health tech firm Zelis Saudi Arabia’s Almoosa Health sets IPO price range, plans to raise SAR1.7bn Saudi Arabia’s Almoosa plans to list 30% stake on local bourse